Deschatelets Pascal 4

What Happened

• Pascal Deschatelets, Chief Scientific Officer of Apellis Pharmaceuticals (APLS), was granted 25,840 restricted stock units (RSUs) on January 28, 2026. The units were reported as acquired at $0.00 (a compensation award rather than a market purchase or sale).

Key Details

• Transaction date: January 28, 2026. Form 4 filed January 30, 2026 (appears timely under Form 4 reporting rules).
• Transaction type/code: Award/Grant (A).
• Shares awarded: 25,840 RSUs; reported acquisition price $0.00 (no cash paid).
• Vesting: Vest 25% annually over four years from the grant date, subject to continued service (Footnote F1).
• Shares owned after transaction: Not specified in the filing.
• No tax withholding, sale, or disposition reported in this filing.

Context

• RSUs are a form of equity compensation that convert to actual shares only as they vest; they are routine compensation for executives and do not represent an immediate market purchase or sale. Such grants are informative about pay and retention but do not necessarily indicate the insider’s view on near-term stock performance.